September 2024 in “Dermatology” This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.
This study found that mesotherapy combined with minoxidil for androgenetic alopecia shows promise with high patient satisfaction and manageable risks, though some uncommon side effects may occur.
March 2023 in “Anais Brasileiros De Dermatologia” This article reviews treatment options for female-pattern hair loss, noting the limited evidence for most therapies and emphasizing that topical minoxidil remains the only well-supported option despite a significant non-response rate.
1 citations
,
August 2022 in “Journal of Dermatological Treatment” In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.
This study evaluated the use of dutasteride mesotherapy for treating androgenetic alopecia in real clinical practice, finding it effective in improving hair loss for both men and women with mild side effects, primarily pain.
2 citations
,
March 2022 in “Journal of The European Academy of Dermatology and Venereology” This letter to the editor presents no new research results; it discusses a combination of dutasteride intralesional microinjections with oral minoxidil versus oral minoxidil alone for treating androgenetic alopecia in men.
8 citations
,
March 2022 in “Journal of Cosmetic Dermatology” This study concluded that mesotherapy appears effective for treating pattern hair loss, but emphasizes a need for more research comparing it to other treatments due to limited sample sizes.
1 citations
,
January 2022 in “Annals of Dermatology” In this South Korean retrospective study, dutasteride improved hair growth more effectively than finasteride in men with androgenic alopecia, and had a similar or possibly lower rate of adverse events, suggesting it as a viable treatment option.
17 citations
,
November 2021 in “Journal of Cosmetic Dermatology” This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.
24 citations
,
September 2020 in “Dermatology and therapy” This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.
59 citations
,
July 2020 in “Journal of The American Academy of Dermatology” This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.
53 citations
,
February 2020 in “Expert Opinion on Pharmacotherapy” This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.
5 citations
,
January 2020 in “Skin appendage disorders” This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.
17 citations
,
January 2020 in “The World Journal of Men's Health” This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.
6 citations
,
December 2019 in “Dermatologic Therapy” This study evaluated oral dutasteride for male androgenetic alopecia in a real-world setting, reporting that it effectively improved hair conditions in 90% of patients using monotherapy, with a good safety profile, particularly at low doses.
52 citations
,
May 2019 in “Journal of The American Academy of Dermatology” This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.
This study summarizes the therapeutic use of mesotherapy using vitamins, trace elements, and stem cell extracts for treating alopecia, noting its effectiveness in addressing both androgenetic alopecia and telogen effluvium as demonstrated in various clinical trials.
24 citations
,
September 2018 in “Lasers in Surgery and Medicine” This study shows that multiphoton microscopy can non-invasively distinguish between scarring and non-scarring alopecia by identifying certain morphological features, but further research is needed to confirm its clinical utility.
15 citations
,
January 2018 in “Acta dermato-venereologica” This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
27 citations
,
March 2017 in “Current Clinical Pharmacology” In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.
24 citations
,
January 2017 in “International Journal of Trichology” 
33 citations
,
August 2016 in “Indian Journal of Dermatology, Venereology and Leprology” In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.
32 citations
,
February 2016 in “Journal of Dermatology” This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.
97 citations
,
January 2014 in “Journal of The American Academy of Dermatology” This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.
26 citations
,
May 2013 in “British Journal of Dermatology” This study provides evidence that a polygenic component contributes to the heritable risk for androgenetic alopecia, indicating the need for further research to identify the complex biological pathways involved.
17 citations
,
June 2012 in “Australasian Journal of Dermatology” This study found that adding low-dose dutasteride to ongoing finasteride treatment significantly improved hair density in a patient with androgenetic alopecia.
41 citations
,
April 2012 in “Journal of The European Academy of Dermatology and Venereology” This study found that mesotherapy with a dutasteride-containing preparation improved hair growth indicators in female pattern hair loss better than saline, with minimal side effects and greater effectiveness in patients with shorter disease duration.
92 citations
,
June 2010 in “Journal of The American Academy of Dermatology” This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.
45 citations
,
January 2008 in “Drugs” This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.
195 citations
,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.
215 citations
,
November 2006 in “Journal of The American Academy of Dermatology” This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.
80 citations
,
August 2002 in “Journal of Dermatology” This study found that combining oral finasteride with topical minoxidil resulted in the greatest improvement in hair growth for male patients with androgenetic alopecia, compared to using any single treatment.
143 citations
,
October 1996 in “Dermatologic Clinics” Too much androgen can cause hair loss; finasteride may help.
48 citations
,
June 1988 in “PubMed” In this study, minoxidil sulfate was found to relax norepinephrine-induced contractions in rabbit mesenteric arteries, possibly by acting as a K+ channel agonist, but it did not relax K+-induced contractions.
